6th Nov 2019 09:36
(Alliance News) - 4D Pharma PLC said on Wednesday that initial clinical observations show that oncology candidate MRx0518 and KEYTRUDA combination is well tolerated in patients with advance disease.
The pharmaceutical company said that clinical observation in collaboration with Merck & Co Inc were to evaluate company's lead oncology candidate MRx0518 in combination with Merck anti-PD-1 theraphy KEYTRUDA in patients with renal cell carcinoma, melanoma, non-small cell lung cancer and bladder cancer.
The initial data revealed that the combination is well tolerated in the first six patients. Two out of six patients showed clinically relevant response in the phase 1/2 study, the company said.
4D Pharma said these are the first observations from an oncology study in humans involving a live biotherapeutic product.
Alex Stevenson, chief scientific officer, said: "Although more work will be required to establish the robustness of the responses observed and their frequency in a larger number of patients, we are pleased to be able to report these initial results - the first from an oncology study involving a live biotherapeutic product."
"These initial findings further support our continued investment into our oncology franchise," Stevenson said.
4D Pharma shares were down 8.0% in London at 101.70 pence each on Wednesday
By Loreta Juodagalvyte; [email protected]
Copyright 2019 Alliance News Limited. All Rights Reserved.
Related Shares:
DDDD.L